Co-occurring genomic alterations in non-small-cell lung cancer
4.9 (596) · $ 20.99 · In stock
Cancers, Free Full-Text
Integrative analysis of a large real-world cohort of small cell
PDF] Co-occurring genomic alterations define major subsets of KRAS-mutant lung adenocarcinoma with distinct biology, immune profiles, and therapeutic vulnerabilities.
A Look at NSCLC and Its Current and Emerging Therapies
Toward personalized treatment approaches for non-small-cell lung
PDF] Effects of Co-occurring Genomic Alterations on Outcomes in
Molecular Diagnostic and Precision Medicine in Non-Small Cell
Landscape of EGFR mutations in lung adenocarcinoma: a single institute experience with comparison of PANAMutyper testing and targeted next-generation sequencing
PDF) Direct Targeting KRAS Mutation in Non-Small Cell Lung Cancer: Focus on Resistance
Gene-network analysis predicts clinical response to immunotherapy in patients affected by NSCLC - Lung Cancer
Genomic and immunological profiles of small-cell lung cancer
PDF] Co-occurring genomic alterations define major subsets of KRAS-mutant lung adenocarcinoma with distinct biology, immune profiles, and therapeutic vulnerabilities.
